Phenytoin: Analysis of core anti-epileptic and arrhythmia drugs

Phenytoin is a classic drug widely used in the treatment of epilepsy and cardiac arrhythmias. Its core function is to suppress abnormal electrical activity. This article will start from four parts: pharmacological mechanism, clinical application, precautions and production information, focusing on analyzing its therapeutic value and limitations. First, we outline the core status of its dual indications, then discuss in detail the application differences between the nervous system and cardiovascular system, and finally summarize the medication risks and common dosage forms on the market to provide readers with a comprehensive reference.

Pharmacological properties and therapeutic targets

Phenytoin exerts its medicinal effect by blocking voltage-dependent sodium channels, significantly reducing the abnormal excitability of neurons and cardiomyocytes. In the treatment of epilepsy, it can effectively suppress high-frequency discharges in brain focus areas, especially forGrand mal and focal seizuresThe effect is significant; in the field of arrhythmia, ventricular tachycardia is controlled by prolonging the refractory period of the atrioventricular node. It is worth noting that the therapeutic window of this drug is narrow, and the blood concentration needs to be maintained in the range of 10-20 μg/ml. Excessive dosage can easily cause neurotoxic reactions such as nystagmus.

Differentiated performance in clinical applications

For patients with epilepsy, phenytoin is often used as a second-line drug when drugs such as carbamazepine are ineffective. The American Academy of Neurology guidelines state that its effectiveness in controlling seizures is about 60%-70%. In cardiovascular terms, in 2020 the European Society of Cardiology classified phenytoin asArrhythmia caused by digitalis poisoningalternatives. Clinical data show that intravenous injection of 300 mg can restore normal heart rhythm in 80% of patients with premature ventricular contractions (see table below).

Risks of use and contraindications for special groups

Long-term use may lead to gum hyperplasia (incidence 15%-20%) and osteoporosis. It is contraindicated for pregnant women (FDA Pregnancy Class D) as it may cause fetal malformations. The INR value needs to be closely monitored when used in combination with warfarin, as the hepatic enzyme induction effect of phenytoin will accelerate the metabolism of anticoagulant drugs. Elderly patients should reduce the dose by 30%, and those with liver dysfunction need to monitor blood drug concentrations.

Market overview and medication guidance

Major domestic manufacturers include Shanghai Xinyi Pharmaceutical Factory (trade nameDalunding), Shandong Xinhua Pharmaceutical, etc., the dosage forms include 50mg tablets and 250mg injections. The principle of "starting with a small dose" should be followed when using it. It takes 3-4 weeks for oral administration to reach a steady-state concentration. The 2019 version of the "Chinese Guidelines for the Diagnosis and Treatment of Epilepsy" emphasizes that blood routine and liver function should be tested regularly during treatment. Although new anti-epileptic drugs continue to emerge, phenytoin still maintains an important position in primary hospitals due to its precise efficacy and price advantages.

Quote sources:
1. "Clinical Pharmacology" (8th edition) edited by Li Jun
2. U.S. FDA drug package insert (NDA 008762)
3. European Society of Cardiology 2020 Arrhythmia Guidelines
4. Manufacturers: Shanghai Xinyi Pharmaceutical Factory (Dalentin®), Shandong Xinhua Pharmaceutical (Phenytoin Tablets)